---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-003326"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:45:01.509380+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Corvus Pharma Q1 net loss $8.3M; cash $62.9M; Phase 2 NSCLC trial planned

## Summary
- Net loss $8.3M for Q1 2022 vs $11.6M in Q1 2021; R&D expenses down to $5.1M from $8.2M.
- Cash, cash equivalents and marketable securities $62.9M as of March 31, 2022 vs $69.5M at Dec 31, 2021.
- Plans Phase 2 randomized trial of mupadolimab + chemo in front-line NSCLC in 2022 with ~150 patients.
- Phase 1b/2 ciforadenant + ipilimumab/nivolumab in front-line RCC to start Q3 2022 via Kidney Cancer Consortium.
- Phase 1/1b CPI-818 (ITK inhibitor) continues enrolling T-cell lymphoma patients; data expected later 2022.

## SEC filing metadata
- accession: 0001171843-22-003326
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184322003326/0001171843-22-003326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184322003326/f8k_050522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-003326
- JSON: https://secwatch.observer/filing/0001171843-22-003326.json
- Plain text: https://secwatch.observer/filing/0001171843-22-003326.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.